Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

19 results
Display

Biomarkers and diagnostic tools for lung cancer

Lee SH, Lee EH, Kim EY, Choi YJ, Cha YJ, Chang YS

Lung cancer is the leading cause of cancer-related deaths in developing to advanced countries worldwide. The incidence rate of lung cancer in Korea has been increasing steadily since 1997. Statistics...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Prognostic Value of Serum Soluble Programmed Death-Ligand 1 and Dynamics During Chemotherapy in Advanced Gastric Cancer Patients

Park W, Bang JH, Nam AR, Jin MH, Seo H, Kim JM, Oh KS, Kim TY, Oh DY

Purpose The soluble form programmed death-ligand 1 (sPDL1) has immunosuppressive properties and is being studied as a candidate biomarker for immuno-oncology drug development. We measured the serum sPDL1 at pre-and...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Development of an Operational Plan for the Liquid Biopsy External Quality Assessment Program in Korea

Ahn S, Kim HK, Kim JH, Lee W, Chun S, Lee WG, Min WK

Background: Liquid biopsy is a useful assay for the diagnosis, treatment, and prognosis prediction of solid tumors and its clinical application is expanding. Therefore, the need for developing an External...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Role of Liquid Biopsies in Colorectal Cancer

Kim SH, Keum B

  • KMID: 2503587
  • J Dig Cancer Rep.
  • 2020 Jun;8(1):56-60.
In recent years, liquid biopsy has received immense attention. Liquid biopsy is a minimally invasive method used for obtaining biological fluids including urine, pleural fluid and, mostly, peripheral blood. Liquid...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Current status and future perspectives of liquid biopsy in non-small cell lung cancer

Chang S, Hur JY, Choi YL, Lee CH, Kim WS

With advances in target therapy, molecular analysis of tumors is routinely required for treatment decisions in patients with advanced non-small cell lung cancer (NSCLC). Liquid biopsy refers to the sampling...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
ESR1 Mutation Detection and Dynamicsin Meningeal Carcinomatosis in BreastCancer

Carausu M, Melaabi S, Pierga JY, Bidard FC, Cabel L

ESR1 mutation is frequently encountered in hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC), especially after aromatase inhibitor (AI) therapy, as a mechanism of resistance to...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Liquid biopsy using extracellular vesicle–derived DNA in lung adenocarcinoma

Kim IA, Hur JY, Kim HJ, Lee SE, Kim WS, Lee KY

Blood liquid biopsy has emerged as a way of overcoming the clinical limitations of repeat biopsy by testing for the presence of acquired resistance mutations to therapeutic agents. Despite its...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Clinical Application of Circulating Tumor Cells in Gastric Cancer

Lee MW, Kim GH, Jeon HK, Park SJ

Early detection and accurate monitoring of cancer is important for improving clinical outcomes. Endoscopic biopsy and/or surgical resection specimens are the gold standard for diagnosing gastric cancer and are also...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Circulating Tumor Cells: Liquid Biopsy for Early Detection of Cancer

Mwesige B, Yeo SG, Yoo BC

Cancer is a complex, heterogeneic, and dynamic disease involving multiple gene-environment interactions, and affecting numerous biological pathways. As such, the development of reliable and robust non-invasive platforms constitutes a vital...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Real-World Analysis of the Efficacy of Rebiopsy and EGFR Mutation Test of Tissue and Plasma Samples in Drug-Resistant Non-Small Cell Lung Cancer

Hong MH, Kim HR, Ahn BC, Heo SJ, Kim JH, Cho BC

PURPOSE: Standard treatment for cases of non-small cell lung cancer (NSCLC) exhibiting acquired drug resistance includes tumor rebiopsy, epidermal growth factor receptor (EGFR) mutation testing (e.g., for T790M mutations), and...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Provisional Guideline Recommendation for EGFR Gene Mutation Testing in Liquid Samples of Lung Cancer Patients: A Proposal by the Korean Cardiopulmonary Pathology Study Group

Shin DH, Shim HS, Kim TJ, Park HS, Choi YL, Kim WS, Kim L, Chang SH, Song JS, Kim HJ, Han JH, Lee CH, Lee GK, Jang SJ, Korean Cardiopulmonary Pathology Study Group

Liquid biopsy for detection of mutation from circulating tumor DNA is a new technology which is attractive in that it is non-invasive. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Detection of KRAS mutations in plasma cell-free DNA of colorectal cancer patients and comparison with cancer panel data for tissue samples of the same cancers

Min S, Shin S, Chung YJ

Robust identification of genetic alterations is important for the diagnosis and subsequent treatment of tumors. Screening for genetic alterations using tumor tissue samples may lead to biased interpretations because of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Circulating Cell-free Tumor Nucleic Acids in Gastric Cancer

Lee HJ, Lee SM

Gastric cancer is still the leading cause of cancer deaths, especially in Asian countries. Recently, many studies have analyzed cell-free nucleic acids (cfNAs) circulating in the blood, for the early...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Current Methods of Circulating Tumor Cell Detection

Lim M, Cho YK

Liquid biopsy, the analysis of circulating biomarkers from peripheral blood, such as circulating tumor cells (CTCs) and circulating tumor DNA, and exosomes, offers a less invasive, new source of cancer-derived...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Liquid Biopsy: Current Status and Future Perspective in Gastric Cancer and Helicobacter Infection

Kang EA, Han YM, Park JM, Yoo IK, Hong SP, Hahm KB

Precision medicine stands for 4Ps - precise, preventive, participatory, and personal; in which “precision” is important because the current modern medicine starts from “trial and error,” and “one does not...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Unmasking molecular profiles of bladder cancer

Piao XM, Byun YJ, Kim WJ, Kim J

Precision medicine is designed to tailor treatments for individual patients by factoring in each person's specific biology and mechanism of disease. This paradigm shifted from a “one size fits all”...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Extracellular Vesicles and the Promise of Continuous Liquid Biopsies

Armstrong , Wildman DE

The rapid and accurate diagnosis of patients with minimally invasive procedures was once only found in science fiction. However, the discovery of extracellular vesicles (EVs) and their near ubiquity in...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Cell-Free DNA in Oncology: Gearing up for Clinic

Ulrich BC, Paweletz C

In the past several years, interest in the clinical utility of cell-free DNA as a noninvasive cancer biomarker has grown rapidly. Success in the development of plasma genotyping assays and...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Circulating Tumor DNA in a Breast Cancer Patient's Plasma Represents Driver Alterations in the Tumor Tissue

Lee J, Cho SM, Kim MS, Lee SH, Chung YJ, Jung SH

Tumor tissues from biopsies or surgery are major sources for the next generation sequencing (NGS) study, but these procedures are invasive and have limitation to overcome intratumor heterogeneity. Recent studies...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr